The Second Affiliated Hospital of Guangxi Medical University
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, cranial nerve neuropathy, eye disorder, nervous system disorder, optic nerve disorder, optic neuritis, vision disorder | Recruiting | Not stated | 2026-09-25 | NCT07623252 | |
| Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery | Cancer Surgery; Dexmedetomidine; Elderly; Long-Term Survivors | Recruiting | Not applicable | 2025-07-31 | NCT06030804 | |
| A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 2 | 2025-07-24 | NCT07083739 | |
| A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2025-05-20 | NCT06900920 |